🚀 VC round data is live in beta, check it out!
Ortivus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ortivus and similar public comparables like Etropal, iZafe Group, BioRegenx, Balsm Alofoq and more.
Ortivus Overview
About Ortivus
Ortivus AB is a supplier of mobile solutions for modern emergency medical care. Its product portfolio includes MobiMed Smart and CoroNet.
Founded
1985
HQ
Employees
44
Website
Sectors
Financials (FY)
EV
$15M
Ortivus Financials
Ortivus reported last fiscal year revenue of $8M and negative EBITDA of ($2M).
In the same fiscal year, Ortivus generated $3M in gross profit, ($2M) in EBITDA losses, and had net loss of ($2M).
Ortivus P&L
In the most recent fiscal year, Ortivus reported revenue of $8M and EBITDA of ($2M).
Ortivus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $8M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 40% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (20%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (19%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (30%) | XXX | XXX | XXX |
| Net Debt | — | — | $978K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ortivus Stock Performance
Ortivus has current market cap of $14M, and enterprise value of $15M.
Market Cap Evolution
Ortivus' stock price is $0.15.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15M | $14M | -10.3% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrtivus Valuation Multiples
Ortivus trades at 1.9x EV/Revenue multiple, and (9.4x) EV/EBITDA.
Ortivus Financial Valuation Multiples
As of April 11, 2026, Ortivus has market cap of $14M and EV of $15M.
Equity research analysts estimate Ortivus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ortivus has a P/E ratio of (5.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14M | XXX | $14M | XXX | XXX | XXX |
| EV (current) | $15M | XXX | $15M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (9.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (9.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.7x | XXX | XXX | XXX |
| P/E | — | XXX | (5.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ortivus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ortivus Margins & Growth Rates
Ortivus' revenue in the last fiscal year declined by (9%).
Ortivus' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Ortivus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (9%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (20%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ortivus Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| iZafe Group | XXX | XXX | XXX | XXX | XXX | XXX |
| BioRegenx | XXX | XXX | XXX | XXX | XXX | XXX |
| Balsm Alofoq | XXX | XXX | XXX | XXX | XXX | XXX |
| Jin Medical International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ortivus M&A Activity
Ortivus acquired XXX companies to date.
Last acquisition by Ortivus was on XXXXXXXX, XXXXX. Ortivus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ortivus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOrtivus Investment Activity
Ortivus invested in XXX companies to date.
Ortivus made its latest investment on XXXXXXXX, XXXXX. Ortivus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ortivus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ortivus
| When was Ortivus founded? | Ortivus was founded in 1985. |
| Where is Ortivus headquartered? | Ortivus is headquartered in Sweden. |
| How many employees does Ortivus have? | As of today, Ortivus has over 44 employees. |
| Who is the CEO of Ortivus? | Ortivus' CEO is Gustaf Nordenhok. |
| Is Ortivus publicly listed? | Yes, Ortivus is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Ortivus? | Ortivus trades under ORTI B ticker. |
| When did Ortivus go public? | Ortivus went public in 1995. |
| Who are competitors of Ortivus? | Ortivus main competitors are Etropal, iZafe Group, BioRegenx, Balsm Alofoq. |
| What is the current market cap of Ortivus? | Ortivus' current market cap is $14M. |
| What is the current revenue of Ortivus? | Ortivus' last fiscal year revenue is $8M. |
| What is the current EV/Revenue multiple of Ortivus? | Current revenue multiple of Ortivus is 1.9x. |
| Is Ortivus profitable? | No, Ortivus is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.